VALIDATE Industry Seminar: Addressing Pathogen and Human Diversity - Watch Now


About the event: This event took place on 27 April 2021.

COVID has provided a stark example of pathogenic mutation.  The variation of impact of infection on the population similarly shows that human responses are variable.  This highlights a key need in vaccinology of identifying and developing technologies which are able to address diversity, whilst maintaining safety and achieved cost-effectively.  This session explores the options and particularly highlight ImmBio’s approach, exemplified by its lead development against Streptococcus pneumoniae, a good example of a bacteria in circulation with a wide array of genotypes.  Whilst there are products available providing good protection against specific serotypes, as defined by the polysaccharide capsule used in the current class of vaccines, ImmBio’s focus is a multiple-protein approach.  

A new approach raises new regulatory and manufacturing challenges but again drawing on COVID experience, vaccinology may be able to able to benefit from a paradigm shift in addressing risk and benefit, enhancing the attractiveness of investing in new vaccines.



About the ​​​​​​Speaker: Graham Clarke is ImmBio’s Chair and previously its CEO. Originally a biophysicist, he has held senior-level positions including at SmithKline Beecham, GSK and GE Healthcare.  He is now a non-executive on a number of boards, including the UK’s Medicine Discovery Catapult and NHS Health Research Authority. He has also been a member of the UK government’s COVID therapeutic task force.